This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Momentum Stocks Worth Investing in via Driehaus Strategy
by Zacks Equity Research
Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.
ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 45.36% and 7.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is ICU Medical (ICUI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is ICU Medical, Inc. (ICUI) Outperforming Other Medical Stocks This Year?
Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI
by Zacks Equity Research
Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI
Shrug Off Market Volatility With These 5 Low Beta Stocks
by Zacks Equity Research
We develop a strategy that clearly shows that less risky stocks have the potential to reward shareholders with impressive returns only when certain parameters are considered.
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural
by Zacks Equity Research
Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural
Rely on Driehaus Strategy and Buy These 5 Momentum Stocks
by Zacks Equity Research
Investors with high risk-tolerance can invest in momentum stocks using Driehaus Strategy.
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
by Zacks Equity Research
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
Boost Immunity to Market Volatility With 5 Low-Beta Stocks
by Zacks Equity Research
We have developed a strategy which clearly shows that stocks with low risk could also reward investors with handsome returns.
ICU Medical (ICUI) Hits a 52-Week-High, Can the Run Continue?
by Zacks Equity Research
ICU Medical, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for ICUI for clues.
Fresenius Medical (FMS) Q4 Earnings Beat, View Impressive
by Nabaparna Bhattacharya
Higher sales of dialyzers, machines, peritoneal dialysis products, renal pharmaceuticals, bloodlines and products for acute care boost Fresenius Medical (FMS) in Q4.
Here's Why You Should Invest in Bio-Rad (BIO) Right Now
by Zacks Equity Research
Positive tidings on the regulatory front and strong fourth-quarter performance boost investors' confidence in Bio-Rad (BIO).
Veeva Systems Rides on Strong Q4 & Cloud-Based Applications
by Zacks Equity Research
Industry expertise and expanding product portfolio in cloud-based solutions to bolster Veeva Systems' (VEEV) prospects.
Cerner Collaborates With Salesforce, Focuses on AI Trends
by Zacks Equity Research
Cerner (CERN) has been in the headlines, courtesy of its consistent efforts to digitize electronic health record systems.
Ecolab Gains From Strength in Global Industrial Segment
by Zacks Equity Research
Ecolab (ECL) witnesses improvement in underlying sales volume and pricing in most business segments.
Will International Expansion Aid JD.com (JD) Q4 Earnings?
by Zacks Equity Research
Strong growth in e-commerce business and international expansion are likely to drive JD.com's fourth-quarter earnings.
MedTech's Long-Term Prospects Outweigh Near-Term Risks
by Mark Vickery
A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.
Product Innovation Drives Illumina, Downbeat Margins a Woe
by Zacks Equity Research
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
PRA Health (PRAH) Hits 52-Week High on Multiple Positives
by Zacks Equity Research
PRA Health (PRAH) touches 52-week high on consistent revenue performance and Symphony Health integration.
Zimmer Biomet Suffers a Dull Knee Business & Supply Delay
by Zacks Equity Research
Zimmer Biomet (ZBH) fights challenges like supply delay of certain products that curb its capacity to regain lost US-based customers and net in the new ones.
ICU Medical (ICUI) in Focus: Stock Moves 10.2% Higher
by Zacks Equity Research
ICU Medical (ICUI) saw its shares rise over 10% on the day.
Should You Buy ICU Medical (ICUI) Ahead of Earnings?
by Zacks Equity Research
ICU Medical (ICUI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.